(0.27%) 5 475.09 points
(0.13%) 39 170 points
(0.83%) 17 879 points
(0.04%) $83.41
(-0.08%) $2.48
(0.12%) $2 341.70
(0.50%) $29.76
(0.40%) $992.70
(0.05%) $0.931
(0.17%) $10.66
(0.05%) $0.791
(-0.01%) $86.75
@ $78.38
Issued: 27 Jun 2024 @ 10:32
Return: 3.38%
Previous signal: Jun 27 - 09:30
Previous signal:
Return: 1.78 %
Live Chart Being Loaded With Signals
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States...
Stats | |
---|---|
Today's Volume | 712 439 |
Average Volume | 674 106 |
Market Cap | 3.85B |
EPS | $-1.440 ( Q1 | 2024-05-06 ) |
Next earnings date | ( $-1.320 ) 2024-08-05 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-12.56 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $1.740 (2.15%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-07 | Mahony Susan | Buy | 5 799 | Stock Option (Right to Buy) |
2024-06-07 | Coleman Mark | Buy | 5 799 | Stock Option (Right to Buy) |
2024-06-07 | Jeffs Roger | Buy | 5 799 | Stock Option (Right to Buy) |
2024-06-07 | Saad Mark E | Buy | 5 799 | Stock Option (Right to Buy) |
2024-05-29 | Jacobson Mark L. | Buy | 13 693 | Common Stock |
INSIDER POWER |
---|
51.04 |
Last 99 transactions |
Buy: 1 985 054 | Sell: 314 752 |
Volume Correlation
Axsome Therapeutics Inc Correlation
10 Most Positive Correlations | |
---|---|
OZEM | 1 |
BDSX | 0.866 |
AAPD | 0.863 |
LTRX | 0.863 |
CBFV | 0.861 |
DBX | 0.86 |
SMSI | 0.859 |
GASS | 0.856 |
SSP | 0.849 |
LDWY | 0.848 |
10 Most Negative Correlations | |
---|---|
SEMPX | -0.912 |
FDCF | -0.904 |
PRCNX | -0.892 |
MPIEX | -0.888 |
NRIX | -0.884 |
HOOD | -0.88 |
ALTEX | -0.88 |
AKLI | -0.879 |
MACSX | -0.878 |
VNOM | -0.877 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Axsome Therapeutics Inc Correlation - Currency/Commodity
Axsome Therapeutics Inc Financials
Annual | 2023 |
Revenue: | $270.60M |
Gross Profit: | $237.70M (87.84 %) |
EPS: | $-5.27 |
FY | 2023 |
Revenue: | $270.60M |
Gross Profit: | $237.70M (87.84 %) |
EPS: | $-5.27 |
FY | 2022 |
Revenue: | $50.04M |
Gross Profit: | $44.84M (89.61 %) |
EPS: | $-4.86 |
FY | 2021 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-3.47 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Axsome Therapeutics Inc
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly absorbed, multi-mechanistic, and investigational medicine that has completed two Phase III trials for the acute treatment of migraine; AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is in Phase III trial to treat narcolepsy; and AXS-14, a novel, oral, and investigational medicine that is in Phase III trial for the treatment of fibromyalgia. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators